Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Creative Commons License

He A., Spelman T., Jokubaitis V., Havrdova E., Horakova D., Trojano M., ...Daha Fazla

JAMA NEUROLOGY, cilt.72, sa.4, ss.405-413, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 72 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1001/jamaneurol.2014.4147
  • Dergi Adı: JAMA NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.405-413
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain.